Holen Sie sich die Stockscreener-App
162.18
0.65%
1.0068
Schlusskurs vom Vortag:
$161.17
Offen:
$161.86
24-Stunden-Volumen:
137.53K
Relative Volume:
0.12
Marktkapitalisierung:
$12.52B
Einnahmen:
$8.27B
Nettoeinkommen (Verlust:
$173.28M
KGV:
74.69
EPS:
2.1712
Netto-Cashflow:
$785.90M
1W Leistung:
-0.83%
1M Leistung:
-3.86%
6M Leistung:
+7.72%
1J Leistung:
+2.77%
1-Tages-Spanne:
$160.46
$164.65
1-Wochen-Bereich:
$150.85
$167.51
52-Wochen-Spanne:
$66.57
$203.91
Icon Plc Stock (ICLR) Company Profile
Firmenname
Icon Plc
Sektor
Branche
Telefon
-
Adresse
-
Compare ICLR vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
162.29 | 13.02B | 8.27B | 173.28M | 785.90M | 2.1712 |
TMO
Thermo Fisher Scientific Inc
|
587.54 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.95 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
589.31 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
319.10 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
144.80 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2026-02-23 | Hochstufung | Jefferies | Hold → Buy |
| 2026-02-18 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-17 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-02-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-08 | Herabstufung | Truist | Buy → Hold |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-09-09 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-03 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-09-18 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2023-12-15 | Eingeleitet | Truist | Buy |
| 2023-09-13 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-17 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-09-07 | Eingeleitet | UBS | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-14 | Eingeleitet | Citigroup | Neutral |
| 2021-04-13 | Fortgesetzt | BofA Securities | Neutral |
| 2021-04-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Equal Weight |
| 2021-03-01 | Hochstufung | UBS | Neutral → Buy |
| 2021-02-26 | Hochstufung | Truist | Hold → Buy |
| 2020-07-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-04-20 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Hold |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-09-23 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-25 | Hochstufung | Mizuho | Neutral → Buy |
| 2018-10-26 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Eingeleitet | UBS | Sell |
| 2018-04-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Bestätigt | Mizuho | Neutral |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-10-27 | Bestätigt | Barclays | Equal Weight |
| 2017-09-11 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-31 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-27 | Bestätigt | Mizuho | Neutral |
| 2017-06-29 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Icon Plc Aktie (ICLR) Neueste Nachrichten
ICLR Looks 20.5% Undervalued on GF Value™ - GuruFocus
ICON plc stock rises on Anthropic deal (ICLR:NASDAQ) - Seeking Alpha
ICON plc Announces Multi-Year Collaboration With Anthropic To Bring Frontier AI To Clinical Trials - marketscreener.com
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials - Business Wire
ICON PLC expected to post earnings of $2.51 a shareEarnings Preview - TradingView
ICON PLC (ICLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ICON PLC (ICLR) Cash Flow - TradingKey
ICON PLC (ICLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Icon Plc (ICLRN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Icon Plc (ICLRN) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
What Just Happened at ICON (ICLR) and Why Did Shares Soar - Kavout | AI
ICON PLC (ICLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ICLR|ICON PLC|Price:170.260|Chg%:+2.980 - TradingKey
ICLR|ICON PLC|Price:168.602|Chg%:+2.842 - TradingKey
ICON PLC (ICLR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Hybrid Clinical Research Job at ICON plc | Apply Online Now! - BioTecNika
ICON PLC (ICLR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ICLR: Icon Plc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Earnings Preview: Icon PLC to Report Financial Results Post-market on July 29 - 富途牛牛
Icon Plc (ICLRN) Earnings Dates, Call Summary & Reports - TipRanks
ICON Plc Shows Signs of Recovery Amid Industry HeadwindsROE Trend Analysis - dars.gov.et
Icon PLC (ICLR) Up 5.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
ICON Plc (ICLR) is Strengthening After Challenges - Yahoo Finance
ICON Schedules Second Quarter 2026 Earnings Conference Call - BioSpace
ICON Schedules Second Quarter 2026 Earnings C - Moomoo
ICON plc to announce Q2FY26 results on July 29 - scanx.trade
ICON plc (NASDAQ: ICLR) schedules Q2 2026 earnings results call - Stock Titan
Press Release: ICON Schedules Second Quarter 2026 Earnings Conference Call - Moomoo
Icon defends claim it left investors with ‘billions in losses’ - The Times
ICON plc Q1 2026 Earnings: EPS Beat Lifts Results, Yet Stock Declines 1.21%Earnings Call Q&A - dars.gov.et
ICON PLC : Leerink Partners Raises Target Pri - Moomoo
Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline - Yahoo Finance
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.
ICON Plc (ICLR) Stock Analysis: A Healthcare Giant With 7.81% Potential Upside - DirectorsTalk Interviews
ETFs Investing in ICON Plc Stocks - TradingView
Icon reiterates 2026 guidance of $7.85B-$8.15B revenue and $10-$11 EPS amid 1.42x net book-to-bill - MSN
Prosight Management, LP's Icon PLC(ICLR) Holding History - GuruFocus
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm - mydailyrecord.com
ICON plc shares drop after internal probe into accounting practices announced - Pluang
ICON plc (ICLR) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
RBC Capital Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $185 - 富途牛牛
ICON Stock and the CRO Trends Shaping Its Next Growth Phase - The Globe and Mail
ICON plc highlights its position in global clinical research. The Nasdaq-listed group continues to b - Ad-hoc-news.de
ICON Public Limited Company (ICLR) Fell Due to Uncertainty Surrounding Reported Earnings - Yahoo Finance
ICON plc outlines its role in global clinical research as a Nasdaq-listed CRO - ad-hoc-news.de
Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset? - TradingView
ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base - TradingView
Icon PLC | 3: Initial statement of beneficial ownership of securities- O'Neill Julie - Moomoo
ICON shares rise as earnings beat and CEO flags strong booking momentum - MSN
ICLRIcon Plc Options - Finviz
ICON plc. Shares trade on Nasdaq amid steady business backdrop. - AD HOC NEWS
Finanzdaten der Icon Plc-Aktie (ICLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):